In contrast, few studies have assessed the reliability of anti‐BRAF‐V600E immunohistochemistry (IHC) in CNS tumors (Behling et al., 2016; Chappé et al., 2013; Long et al., 2013). This evidence concerns the gene BRAF and central nervous system neoplasm.